Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer

Current Opinion in Oncology

Volumn 11, Issue 3, 1999, Pages 187-190

  Wheeler, Richard H ^a   Spencer, Sharon ^b,c   Buchsbaum, Donald ^b   Robert, Francisco ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M225; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG UPTAKE; HEAD AND NECK CANCER; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0032894562     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199905000-00009     Document Type: Review

References (40)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 1998, 48:31-48.
2. Diammer N, Hong WK: Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993, 85:95-111.
3. Sloan DS, Geopfert H: Conventional therapy of head and neck. Head Neck Cancer 1991, 5:601-625.
4. Department of Veterans Affairs, Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991, 324:1685-1690.
5. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst, 1996, 88:890-899.
6. Lefebvre JL, Wolf G, Luboinski B, Bourkis J, Domenge C, Sancho-Garnier H, et al.: Meta-analysis of chemotherapy in head and neck cancer (MACHNC): 2. Larynx preservation using neoadjuvant chemotherapy (CT) in laryngeal and hypopharyngeal carcinoma [abstract]. Proc Am Soc Clin Oncol 1998, 17:382a.
7. Al-Sarraf M, LeBlanc M, Shanker Giri PG, Fu KK, Cooper J, Vuong T, et al.: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998, 16:1310-1317.
8. El Sayed S, Nelson N: Adjuvant and adjunctive chemotherapy in the management of squamous cell cancer of the head and neck: a meta-analysis of prospective and randomized trials. J Clin Oncol 1996, 14:838-847.
9. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al.: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992, 10:257-263.
10. Forastiere AA, Mitch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al.: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992, 10:257-263.
11. Forastiere AA, Shank D, Neuberg, D, Taylor SG IV, DeConti RC, Adams G: Final report of a Phase II evaluation of Paclitaxel in patients with advanced squamous cell carcinoma of the head and neck. Cancer 1998, 82:2270-2274.
12. Posner M, Dreyfuss A, Clark J, Norris C, Rasse R, Lucarine J, et al.: Docetaxel for advanced incurable squamous cell carcinoma of the head and neck (SCCHN) [abstract 872]. Proc Am Soc Clin Oncol 1996, 15:311.
13. Schoffske P, Wanders J, Catimel G, Heinrich B, Schrijvers D, Gore M, et al.: Docetaxel and cisplatin: a highly active regimen for squamous cell carcinoma of the head and neck [abstract 871]. Proc Am Soc Clin Oncol 1996, 15:310.
14. Flood WA, Lee DJ, Trotti A, DeConti R, Endicott J, Spencer S, et al.: A phase I study of weekly paclitaxel and cisplatin concurrent with postoperative radiation therapy for treatment of high-risk patients with squamous cell cancer of the head and neck [abstract 585]. Proc Am Soc Clin Oncol 1996, 15:314.
15. Forastiere AA, Leong T, Murphy B, Rowensky E, DeConti R, Karp D, Adams G: A Phase II trial of high-dose paclitaxel and cisplatin + GCSF versus low-dose paclitaxel and cisplatin in patients with advanced squamous cell carcinoma of the head and neck (HNSCC): an Eastern Cooperative Cancer Group trial [abstract 1367]. Proc Am Soc Clin Oncol 1997, 16:384a.
16. Carey TE, Kimmel KA, Schwartz DR, Richter DE, Baker SR, Krause CJ: Antibodies to human squamous cell carcinoma. Otolaryngol Head Neck Surg 1983, 91:482-491.
17. 2. J Nucl Med 1994, 35:775-783.
18. DeBree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS: Radioimmunoscintigraphy and biodistribution of technetium 99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1995, 1:591-598.
19. 2 in patients with head and neck cancer. Clin Cancer Res 1995, 1:277-286.
20. Carpenter G, Wahl MI: The epidermal growth factor family. In Peptide Growth Factors and Their Receptors. Handbook of Experimental Pharmacology. Edited by Sporn MB, Roberts AB. Heidelberg: Springer-Verlag; 1989.
21. Ulbrich A, Schlesinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61:203.
22. Real FX, Retting WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J: Expression of epidermal growth factor receptor in human cultured cells and tissues. Cancer Res 1986, 46:4726-4731.
23. Van de Vijver MJ, Kumar R, Mendelsohn J: Ligand-induced activation of a431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J Biol Chem 1991, 266:7503-7508.
24. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH: Biological effect in vitro of monoclonal antibodies to human egf receptors. Mol Biol Med 1983, 1:511-529.
25. Masu H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984, 44:1002-1007.
26. Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997, 3:2703-2707. This article summarizes preclinical studies defining the use of Mab to the EGF receptor alone and in combination with antineoplastic agents in vitro and in vivo.
27. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, Mendelsohn J: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993, 85:1327-1333.
28. Fan Z, Baselga J, Masui H, Mondelsohn J: Antitumor effect of anti-eff receptor monoclonal antibodies plus cis-diamminedichloroplatinum (cis-ddp) on well established a431 cell xenografts. Cancer Res 1993, 53:4637-4642.
29. Baselga J, Norton L, Coplan K, Shalaby K, Mendelsohn R: Antitumor activity of paclitaxel in combination with anti-growth factor antibodies in breast cancer xenografts [abstract]. Proc Am Assoc Cancer Res 1994, 35:380.
30. Divgi CR, Welt S, Kris M, Real FX, Yeh SDJ, Gralla R, et al.: Phase I and imaging trial of Indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung cancer. J Natl Cancer Inst 1991, 83:97-104.
31. Khazaeli MB, Saleh MM, Wheeler RH, Huster WJ, Holden H, Carrano R, LoBuglio AF: Phase I trial of multiple large doses of murine monoclonal antibody k017-1a.11: pharmacokinetics and immune response. J Natl Cancer Inst 1988, 80:937-942.
32. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, et al.: Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 1989, 86:4220-4224.
33. McLaughlin P, Grillo-Lopez AJ, Link BK, Leng R, Czuczman MS, Williams ME, et al.: Rituxcimal chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
34. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, et al.: Addition of herceptin (humanized anti-HER-2 antibody) to first line chemotherapy for HER-2 overexpressing metastatic breast cancer (HER-2-MBC) markedly increased anticancer activity: a randomized multinational controlled Phase III trial [abstract 98a]. Proc Am Soc Clin Ocnol 1998, 17:98a. A randomized clinical trial in patients with metastatic breast cancer documents the improved therapeutic response obtained with the combined treatment of standard chemotherapy and the anti-growth factor receptor Mab herceptin compared to conventional chemotherapy alone.
35. Bos M, Mendelsohn J, Bowden C, Pfister D, Cooper MR, Cohen R, et al.: Phase I studies of anti-epidermal growth factor receptor (egfr) chimeric monoclonal antibody c225 in patients with egfr overexpressing tumors [abstract 1381]. Proc Am Soc Clin Oncol 1996, 15:443.
36. Falcey J, Pfister D, Cohen R, Cooper M, Bowden C, Burtness B, et al.: A study of anti-epidermal growth factor receptor (egfr) monoclonal antibody c225 and cisptatin in patients (pts) with head and neck or lung carcinoma. Proc Am Soc Clin Oncol 1997, 16:383a.
37. 2 and a one-compartment, nonlinear model.
38. Perez-Soler R, Shin DM, Donato R, Radinsky R, Khuri F, Glisson BS, et al.: Tumor studies in patients with head and neck cancer treated with humanized anti-epidermal growth factor (egfr) monoclonal antibody c225 in combination with cisplatin [abstract 1514]. Proc Am Soc Clin Oncol 1998, 17:3939.
39. Saleh M, Buschsbaum D, Meredith R, Lalison D, Wheeler R: In vitro and in vivo evaluation of the cytotoxicity of radiation combined with chimeric monoclonal antibody to the epidermal growth factor receptor [abstract 4197]. Proc Am Assoc Cancer Res 1996, 37:612.
40. Ezekiel MP, Robert F, Meredith RF, Spencer SA, Newsome J, Khazaeli MB, et al.: Phase I study of anti-epidermal growth factor receptor antibody c225 in combination with irradiation in patients with advanced squamous cell carcinoma of the head and neck [abstract 1522]. Proc Am Soc Clin Oncol 1998, 17:395a. Clinical study defines the toxicity and tolerance of combined irradiation and an Mab to the EGF receptor in patients with inoperable, untreated squamous cell cancer of the head and neck.